# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price targe...
Jefferies analyst Akash Tewari upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Buy and raises the price ta...
Stifel analyst Paul Matteis maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Hold and raises the price target from $50 t...
Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-...